Literature DB >> 8669107

Quantitating immunosuppression. Estimating the 50% inhibitory concentration for in vivo cyclosporine in mice.

T D Batiuk1, J Urmson, D Vincent, R W Yatscoff, P F Halloran.   

Abstract

Cyclosporine (CsA) blocks T cell responses in vitro by inhibiting the phosphatase activity of calcineurin (CN) and thus preventing the activation of cytokine transcription. In the study presented here, we measured the extent of inhibition of these functions in the tissues of CsA-fed mice. Mice fed increasing doses of CsA were assessed for CsA blood and tissue levels, spleen cell CN activity, ex vivo spleen cell cytokine induction by A23187, and in vivo interferon-gamma induction during an allogeneic response. The CN activity of spleen homogenates and cell suspensions and the ex vivo cytokine responses of spleen cells from CsA-treated mice were inhibited with a 50% inhibitory concentration (IC50) greater than 300 microg/L. The in vivo interferon-gamma response to an allogeneic ascites tumor was also inhibited by CsA treatment, with IC50s between 517 and 886 microg/L. The true IC50 for CsA in vivo may be even higher, as CsA levels in spleen and kidney were 4-fold higher than concomitant blood levels. We conclude that inhibition of CN activity by systemically administered CsA leads to a parallel reduction in cytokine gene induction in response to an allogeneic stimulus. In light of our previous clinical findings that therapeutic levels of CsA in renal transplant patients were associated with only partial inhibition of CN activity, these current results support the concept that partial CN inhibition can account for both the immunosuppression and the immunocompetence of CsA-treated patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8669107     DOI: 10.1097/00007890-199606150-00012

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  4 in total

1.  Evidence that calcineurin is rate-limiting for primary human lymphocyte activation.

Authors:  T D Batiuk; L Kung; P F Halloran
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

2.  Pharmacokinetics and pharmacodynamics of low dose mycophenolate mofetil in HIV-infected patients treated with abacavir, efavirenz and nelfinavir.

Authors:  Olga Millán; Mercè Brunet; Jaume Martorell; Felipe García; Elena Vidal; Isabel Rojo; Montserrat Plana; Teresa Gallart; Tomas Pumarola; Jose M Miró; Jose M Gatell
Journal:  Clin Pharmacokinet       Date:  2005       Impact factor: 6.447

3.  Prosurvival Factors Improve Functional Engraftment of Myogenically Converted Dermal Cells into Dystrophic Skeletal Muscle.

Authors:  Lindsey A Muir; Charles E Murry; Jeffrey S Chamberlain
Journal:  Stem Cells Dev       Date:  2016-09-07       Impact factor: 3.272

4.  Interaction of a specific population of human embryonic stem cell-derived progenitor cells with CD11b+ cells ameliorates sepsis-induced lung inflammatory injury.

Authors:  Sophie P Toya; Fei Li; Marcelo G Bonini; Ignatius Gomez; Mao Mao; Kurt W Bachmaier; Asrar B Malik
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.